SAN DIEGO, June 17, 2020 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr.
Helen Torley, president and chief
executive officer, will be participating in the upcoming BMO 2020
Prescriptions for Success Healthcare Conference, which is being
held as a virtual event. Dr. Torley will participate in a fireside
chat at 3:00 p.m. ET / 12:00 p.m. PT on Tuesday, June 23, 2020.
A live webcast of each event can be accessed through the
"Investors" section of Halozyme's website (www.halozyme.com), and
an archive will be made available for 90 days following each event.
To access a live webcast, please visit Halozyme's website
approximately 15 minutes prior to the presentation to register and
download any necessary audio software.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. Halozyme advises and
supports its biopharmaceutical partners in key aspects of new drug
development with the goal of improving patients' lives while
helping its partners achieve global commercial success. As the
innovators of the ENHANZE® technology, which can reduce
hours-long treatments to a matter of minutes, Halozyme's
commercially-validated solution has positively impacted more than
400,000 patient lives via four commercialized products across more
than 100 global markets. Halozyme and its world-class partners are
currently advancing multiple therapeutic programs intended to
deliver innovative therapies, with the potential to improve the
lives of patients around the globe. Halozyme's proprietary enzyme
rHuPH20 forms the basis of the ENHANZE® technology and
is used to facilitate the delivery of injected drugs and fluids,
potentially reducing the treatment burden of other drugs to
patients. Halozyme has licensed its ENHANZE® technology
to leading pharmaceutical and biotechnology companies including
Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers
Squibb, Alexion and argenx. Halozyme derives revenues from these
collaborations in the form of milestones and royalties as the
Company's partners make progress developing and commercializing
their products being developed with ENHANZE®. Halozyme
is headquartered in San Diego. For
more information visit www.halozyme.com.
Contact:
Al
Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-to-participate-in-the-bmo-2020-prescriptions-for-success-healthcare-conference-301079108.html
SOURCE Halozyme Therapeutics, Inc.